The pharmaceutical market and drug development prognosis in Japan: Current and future perspectives according to pharmacological classes

Abstract

Japan is now the second largest pharmaceutical market in the world. As a unique population, it provides many opportunities for pharmaceutical companies to develop their businesses. However, the market is strictly regulated by the government, and drug prices are determined according to the rules in Japan. Nevertheless, no detailed empirical analyses have been conducted to clarify what opportunities may exist for pharmaceutical companies in the future. In the present article, we reviewed the pros and cons of the Japanese pharmaceutical market including related regulations, discussed our analyses of economic and regulatory science, and provided future perspectives on drug development and the pharmaceutical market in Japan. Specifically, we first clarified the Japanese pharmaceutical market profile using the publically available market database. Second, we reviewed the Japanese pharmaceutical pricing system, and found inconsistencies between the “pricing premium for the promotion of new drug development and the elimination/resolution of off-label use” and “repricing for market expansion” based on our literature review. Finally, we provided future perspectives on the pharmaceutical markets in Japan, as well as the direction of the research and development of new drugs.

Keywords

Drug pricing regulatory science marketing strategy pharmaceutical companies clinical development

Get full access to this article

View all access options for this article.

References

Danzon

Chao

. Does regulation drive out competition in pharmaceutical markets? J Law Econ 2000; 43: 311–358.

Ess

Schneeweiss

Szucs

. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21: 89–103.

Dickson

Redwood

. Pharmaceutical reference prices: how do they work in practice? Pharmacoeconomics 1998; 14: 471–479.

Appleby

Devlin

Parkin

et al.

Searching for cost effectiveness thresholds in the NHS. Health Policy 2009; 91: 239–245.

Adamski

Godman

Ofierska-Sujkowska

et al.

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 2010; 10: 153–153.

Pammolli

Magazzini

Riccaboni

. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 2011; 10: 428–438.

Glenn

. Are we all global now? Local vs. foreign sources of corporate competence: the case of the Japanese pharmaceutical industry. Strategic Management Journal 2004; 25: 865–886.

Shibata

Uemura

Suzuki

. Comparative analysis between the top-selling drugs in the Japanese pharmaceutical market and those in the United States, the United Kingdom, France, and Germany. Ther Innov Regul Sci 2016; 50: 221–227.

Central Social Insurance Medical Council. Pharmaceutical drug price calculation method. 9 April, 2014, http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000043212.pdf (accessed 30 April 2017).

10.

Takayama

Narukawa

. Pharmaceutical pricing and reimbursement in Japan for faster, more complete access to new drugs. Ther Innov Regul Sci 2016; 50: 361–367.

11.

Kurosawa

Tamura

. Japanese drug pricing system: how to balance innovation and the reimbursement system. Folia Pharmacol Jpn 2012; 139: 260–263.

12.

Takayama

Narukawa

. Investigation of factors affecting the degree of price gap between the National Health Insurance Reimbursement Price and the Actual Market Price of New Drugs. Regul Sci Med Product 2016; 6: 295–305.

13.

Kato

Matsui

Hane

et al.

Analysis of New Drug Price Calculation According to National Health Insurance (NHI) Drug Price List in Japan. Regul Sci Med Product 2016; 6: 171–183.

14.

DiMasi

Hansen

Grabowski

et al.

Cost of innovation in the pharmaceutical industry. J Health Econ 1991; 10: 107–142.

15.

DiMasi

Hansen

Grabowski

. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151–185.

16.

Getz

Wenger

Campo

et al.

Assessing the impact of protocol design changes on clinical trial performance. Am J Ther 2008; 15: 450–457.

17.

Getz

Campo

. Trends in clinical trial design complexity. Nat Rev Drug Discov 2017; 16: 307–307.

18.

DiMasi

Feldman

Seckler

et al.

Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 2010; 87: 272–277.

19.

Shimazawa

Ikeda

. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications. Clin Ther 2012; 34: 2104–2116.

20.

Central Social Insurance Medical Council. Minutes of Special Committee on Drug Prices, 23 June 2010, http://www.mhlw.go.jp/shingi/2010/06/s0623-2.html (accessed 30 April 2017).

21.

Central Social Insurance Medical Council. Minutes of Special Committee on Drug Prices, 16 October 2013, http://www.mhlw.go.jp/stf/shingi/0000029032.html (accessed 30 April 2017).

22.

Shibata

Uemura

Suzuki

. Factors that affect the acquisition of Reward Premiums for Promotion of Innovative Drug Discovery in Japan. Ther Innov Regul Sci 2016; 50: 56–65.

23.

Shibata

Uemura

Suzuki

. Impact of premium rewards for the promotion of innovative drug discovery on the Japanese pharmaceutical market: an analysis by therapeutic area. Ther Innov Regul Sci 2016; 50: 49–55.

24.

Central Social Insurance Medical Council. Conceptual diagram of repricing for market expansion, 24 January 2012, http://www.mhlw.go.jp/stf/shingi/2r98520000020zbe-att/2r98520000020zy6.pdf (accessed 30 April 2017).

25.

Central Social Insurance Medical Council. Requirements for repricing for market expansion, 2 November 2011, http://www.mhlw.go.jp/stf/shingi/2r9852000001tu6d-att/2r9852000001tupq.pdf (accessed 30 April 2017).

26.

Shibata

Uemura

Suzuki

. Evaluating the effectiveness of repricing for market expansion in the Japanese Drug Pricing System. Ther Innov Regul Sci 2016; 50: 751–758.

27.

Shibata

Uemura

Chiba

et al.

A comprehensive analysis of factors that contribute to conditional approval and all-case surveillance designations that subsequently lead to shortening of review times in Japan. J Regul Sci 2016; 4: 1–9.

28.

Shibata

Wayama

Tsuyuki

et al.

An empirical study of the prescription pattern of drugs for hematological malignancies in Japan from 2010–2014. Biol Pharm Bull 2017; 40: 894–901.

29.

Shibata

Kawaguchi

Uemura

et al.

Emerging growth of orphan drugs for neurological diseases in Japan: potential benefits for both patients and pharmaceutical companies. J Regul Sci 2016; 4: 7–13.

30.

Prasad

De Jesús

Mailankody

. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol 2017; 14: 381–390.